$0.03
(Market cap
$461 Mln
Revenue (TTM)
$7 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.7
-
Debt to Equity
0
-
Book Value
$1
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
186,640,102
10 Years Aggregate
CFO
$-185.65 Mln
EBITDA
$-283.06 Mln
Net Profit
$-273.71 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ovid Therapeutics (OVID)
| 51.5 | -13.3 | 68.0 | 764.5 | -10.5 | -8.9 | -- |
|
BSE Sensex
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ovid Therapeutics (OVID)
| 74.6 | -70.7 | 73.1 | -42.1 | 39.0 | -44.3 | 71.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ovid Therapeutics (OVID)
|
2.5 | 461.0 | 7.1 | -24.2 | -670.2 | -19.9 | -- | 2.3 |
| 75.0 | 10,557.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 17.3 | |
| 247.1 | 15,262.7 | 867.5 | 506.6 | -2.8 | -- | 28.1 | 26.9 | |
| 76.9 | 10,446.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 50.2 | 12,605.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.4 | |
| 119.0 | 15,772.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 299.5 | 8,827.7 | 417.3 | 225.0 | 42.8 | 18.6 | 40 | 6.9 | |
| 517.3 | 11,925.8 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.0 | |
| 432.8 | 12,360.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.3 | 20.7 | |
| 343.6 | 9,578.0 | 0.0 | -326.5 | -- | -37.2 | -- | 6.8 |
Shareholding Pattern
View DetailsAbout Ovid Therapeutics (OVID)
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a... GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. Read more
-
President, CEO & Chairman
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
-
President, CEO & Chairman
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ovid Therapeutics (OVID)
What is the current share price of Ovid Therapeutics Inc (OVID) Today?
The share price of Ovid Therapeutics Inc (OVID) is $2.47 (NASDAQ) as of 22-May-2026 16:06 EDT. Ovid Therapeutics Inc (OVID) has given a return of -10.54% in the last 3 years.
What is the current PB & PE ratio of Ovid Therapeutics Inc (OVID)?
Since, TTM earnings of Ovid Therapeutics Inc (OVID) is negative, P/E ratio is not available.
The P/B ratio of Ovid Therapeutics Inc (OVID) is 2.32 times as on 22-May-2026, a 43 discount to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.93
|
0.92
|
|
2024
|
-2.51
|
0.97
|
|
2023
|
-4.37
|
2.60
|
|
2022
|
-2.53
|
0.98
|
|
2021
|
1.78
|
1.21
|
What is the 52 Week High and Low of Ovid Therapeutics Inc (OVID)?
The 52-week high and low of Ovid Therapeutics Inc (OVID) are Rs 3.11 and Rs 0.27 as of 24-May-2026.
What is the market cap of Ovid Therapeutics Inc (OVID)?
Ovid Therapeutics Inc (OVID) has a market capitalisation of $ 461 Mln as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ovid Therapeutics Inc (OVID)?
Before investing in Ovid Therapeutics Inc (OVID), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.